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Introduction 
Oesophageal fistula to the airway or mediastinum 
is considered a severe complication of oesophageal 
or bronchial carcinoma. Its occurrence is associated 
with the anatomical relationship between the oe-
sophagus and the trachea and main bronchi. It is es-
timated that during the course of inoperable oesoph-
ageal carcinoma, airway compression is observed in 
30% of patients, while in the cases of 10% of patients 
with bronchial carcinoma oesophageal stenosis and 
progressive dysphagia may be seen [1, 2]. Self-ex-
panding oesophageal and bronchial prostheses, as 
well as bifurcated Y-type silicone prostheses, may be 
used as a means of palliation in these patients, as 
well as chemo- and/or radiotherapy [3–5]. 
Aim
The aim of the study was to determine the effec-
tiveness, tolerance, quality of life, safety and surviv-
al after double stenting procedures as a  means of 
palliation in patients with a oesophago-respiratory 
fistula.
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A b s t r a c t
Introduction: The close anatomical relationship between the oesophagus and bronchial tree results in formation of 
an oesophago-respiratory fistula in a subset of patients with advanced oesophageal or lung cancer. In those patients 
stenting of both the oesophagus and tracheobronchial tree is a valid option of palliative treatment. 
Aim: To determine the effectiveness, tolerance, quality of life, safety and survival after double stenting procedures.
Material and methods: Retrospective analysis of a prospectively collected database was performed, concerning 
consecutive patients with oesophago-respiratory fistulas treated with double stenting. In all patients the degree 
of dysphagia, respiratory function before and after the procedure, and quality of life were evaluated. Partially 
covered oesophageal self-expanding metallic stents (PCESEMS) were used for oesophageal stenting, and silicone 
Y-type or partially covered self-expanding bronchial and tracheal stents (PCASEMS) were used to restore airway 
patency.
Results: Between 2003 and 2015, 31 patients underwent double stenting due to oesophago-respiratory fistulas. 
Twenty-nine patients were diagnosed with oesophageal squamous cell carcinoma and 2 with bronchial carcinoma. 
In all patients, improvement in the general condition and quality of life was observed after airway patency resto-
ration. Two patients required mechanical ventilation due to respiratory failure immediately after the procedure. 
Seven patients with oesophageal fistulas died because of bleeding in the long-term follow-up. Four patients required 
endoscopic re-intervention. Mean survival time was 67.1 days.
Conclusions: Double stenting is an effective procedure improving patients’ quality of life. However, life-threatening 
complications can occur.
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The analysis concerned 31 patients with inoper-
able oesophageal and bronchial carcinoma (24 men 
and 7 women), aged 31–82 years, who underwent 
double stenting of the oesophagus and bronchial 
tree between 2003 and 2015. In all patients the de-
gree of dysphagia and respiratory function before 
and after the procedure were evaluated (Table I). 
Dysphagia was classified using a four-point scale [6]: 
0 – able to swallow all solid foods without dyspha-
gia; 1 – able to swallow solid foods with some diffi-
culty; 2 – able to swallow soft or semisoft foods only; 
3 – able to swallow liquids or saliva.
The degree of airway obstruction and impaired 
respiratory function was evaluated using an origi-
nally designed four-point scale: 0 – airway stenosis 
< 30%, without dyspnoea; 1 – airway stenosis 30–
50%, dyspnoea while walking; 2 – airway stenosis 
50–70%, dyspnoea after several minutes of march-
ing; 3 – subtotal airway stenosis > 70%, dyspnoea 
at rest. 
Patients with oesophageal fistula were classified 
using an originally designed scale according to their 
location: 
–  type I  – oesophago-mediastinal fistula without 
bronchial penetration;
–  type II – oesophageal fistula penetrating to the 
trachea;
–  type III – oesophageal fistula penetrating to the 
bifurcation or main bronchi.
The patients’ general condition and quality of life, 
before and after stenting, was assessed according 
Table I. Demographic and clinical data of patients with oesophago-respiratory fistula
Parameter N Type of fistulas
Type I Type II Type III
Patients 31 5 9 17
Mean age (range) [years] 52.0 (47–58) 53.6 (31–67) 64.8 (42–82) 
Male/female 5/0 6/3 15/2
Type of cancer:
Oesophageal 29 4 9 16
NSCLC 2 1 0 1
Length of infiltration in oesophagus (mean) [cm]:
Oesophagus 5.75 (4–8) 6.57 (4–12) 6.13 (3–10)
NSCLC 3 4 4
Location of stricture in the airway > 30%:
Tracheal 1 5 2
Carina 2 4 13
LMBr 2 0 2
Type of prosthesis:
PCESEMS oesophageal + Y silicon airway stent 4 4 15
PCESEMS (oesophageal) + PCASEMS (tracheal) 1 5 0
PCESEMS (oesophageal) + PCASEMS (bronchial) 0 0 2
Adjuvant therapy:
CTH 4 5 7 
CTH + RTH 2 3 0
NSCLC – non-small-cell lung cancer, LMBr – left main bronchus, PCESEMS – partially covered oesophageal self-expanding metallic stents, PCASEMS – partially 
covered self-expanding metallic stents (tracheal and bronchial), CTH – chemotherapy, RTH – radiotherapy.
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to the Karnofsky scale [7]. Patients with < 40 points 
were excluded from the study.
Criteria for double stenting
Patients with inoperable oesophageal or bronchial 
carcinoma with oesophago-airway fistulas were qual-
ified for double stenting. Prior to the planned proce-
dure the following tests were performed: chest ra-
diogram, oesophageal and bronchial endoscopy, and 
abdominal and chest computed tomography (CT). 
Criteria for double stenting included: tumour lo-
cated ≥ 2 cm from the upper oesophageal sphinc-
ter; endoscopically confirmed fistula penetrating the 
mediastinum or bronchial tree; airway compression 
or infiltration posing a risk of severe airway compro-
mise after expansion of the oesophageal stent.
Stenting technique 
The procedure was performed using general an-
aesthesia. Routinely, airway stenting was performed 
first to avoid its potentially fatal compression by the 
expanding oesophageal stent. 
Prior to implantation of the stent, airway patency 
was restored mechanically using rigid bronchoscopes 
(Karl Storz GmbH, Tuttlingen, Germany) no. 6.5, 7.5 
and 8.5, or using argon plasma coagulation (APC) 
and laser (MY 40 1.3, KLS Martin GmbH & Co. KG, 
Freiburg, Germany). Silicone Y-type (Demed, Mikołów, 
Poland) and partially covered airway self-expanding 
metal stents (PCASEMS) (Ultraflex, Boston Scientific, 
Natick, USA) were used (Photos 1 A–C). The implan-
tation of the Y type prosthesis was performed using 
Freitag forceps, while the self-expanding oesoph-
ageal stent was applied under endoscopic control 
[1–3, 8, 9].
Oesophageal stenting was performed next. En-
doscopically, the stenosis was identified and dilat-
ed using the 8–10 Fr Savary-Gilliard dilators (Cook). 
After dilatation, the length of the involved oesoph-
ageal segment was determined using a  fibreoptic 
endoscope, and the oesophageal prosthesis was 
Photo 1 A–C. Computed tomography scan multi-
planar reconstruction after oesophageal and air-
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introduced. Only partially covered oesophageal 
self-expanding metal stents (PCESEMS) (Ultraf-
lex, Boston Scientific, Natick, USA) were used. The 
length of the stent was chosen with the assumption 
that the proximal and distal end of the prosthesis 
should be situated 3–4 cm from the fistula, and the 
diameter of the stent was 18 or 20 mm. After ex-
pansion of the stent, its position was checked en-
doscopically. 
Follow-up
Routinely, follow-up chest radiogram was ob-
tained on the next day. On the first day after the 
procedure dyspnoea and dysphagia scores were as-
sessed. 
The follow-up period ranged between 1 and 169 
days. Patients were evaluated on the first day after 
surgery and every 30 days thereafter. If the follow-up 
check on site was not feasible, patients were inter-
viewed by phone. During the follow-up visit the pa-
tients’ general condition, dysphagia, and dyspnoea 
were assessed. 
Statistical analysis 
Statistical analysis was performed by means 
of the Statistica 10 PL software package (StatSoft, 
USA). The following tests were used: Gehan-Wilcox-
on’s, Kruskal-Wallis, and the dependent variety re-
gression test, before and after surgery. The analysis 
concerned gender, survival, respiratory function, dys-
phagia, weight loss, Karnofsky score, the use of ad-
juvant chemotherapy and/or radiotherapy. P-value 
< 0.05 was considered as statistically significant.
Results
Patients’ characteristics
Twenty-nine patients with oesophageal squa-
mous cell carcinoma and 2 patients with bronchial 
squamous cell carcinoma were included. Two pa-
tients required emergency stenting, while the re-
mainder underwent elective procedures. All patients 
presented with dyspnoea, dysphagia, weight loss 
ranging between 7 and 35 kg (mean: 7.16 kg), cough 
and general weakness. The mean degree of bron-
chial stenosis was 45.3% (range: 30–70%). Mean 
length of oesophageal stenosis was 5.8 cm (range: 
3–12 cm). Diagnosis was as follows: type I fistula in 
5, type II in 9, and type III in 17 patients (Table I). 
Alleviation of dysphagia and dyspnoea
Oesophageal stenting was performed using 
partially covered self-expanding metal stents in all 
patients. Bronchial stenting was performed using 
the Y-type silicone prostheses in 23 cases, covered 
self-expanding tracheal prostheses in 6, and self-ex-
panding bronchial prostheses in 2 patients (Table II). 
Additionally, 5 patients required percutaneous endo-
scopic gastrostomy at the same time.
Double stenting was technically successful in all 
patients, obtaining proper oesophageal and airway 
patency. Statistically significant regression of dys-
pnoea (2.43 vs. 0.27, p < 0.00001) and dysphagia (2.59 
vs. 0.94, p < 0.00001) was noted (Figures 1 and 2). 
General condition and survival
The mean Karnofsky score improved significant-
ly after double stenting (50.4 vs. 68.3; p = 0.00001) 
(Figure 3). 
Mean survival time in the patient group was 68.1 
days (range: 3–169). The location of the fistula had 
no significant influence on survival. The average sur-
vival time was 68.4 days in fistula type 1, 71.8 days 
in type 2, and 66.0 days in type 3 (p = 0.3).
Adjuvant therapy (radio and/or chemotherapy) 
was used in 21 patients (chemotherapy in 16 and 
radio and chemotherapy in 5 patients) and had no 
influence on survival (p = 0.23). There was no signif-
icant difference considering weight gain before and 
after stenting (–7.86 vs. –0.48 kg, p = 0.087) or influ-
ence of BMI on survival, p = 0.17 (Table II).
Complications 
Minor complications
Nineteen patients complained of mild pain or 
discomfort in the chest after stenting, lasting 1–4 
days and requiring analgesics. In 2 cases, full ex-
pansion of the stent was delayed up to 48 h. Four 
patients complained of difficulties in swallowing as-
sociated with a feeling of a foreign body, lasting for 
3 days after oesophageal prosthesis implantation. 
Eleven patients required bronchoscopy during the 
postoperative period, due to secretion retention in 
the bronchial tree.
Major complications
Massive, fatal bleeding occurred in 1 patient on 
the third day after stenting.
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In 1 patient with oesophago-pericardial fistula 
and pericardial tamponade, massive bleeding oc-
curred during restoration of the patency of the left 
main bronchus, and the patient required mechanical 
ventilation for 10 h. He survived 30 days after implan-
tation of the Y-type bronchial stent, and 329 days af-
ter the diagnosis of the oesophago-pericardial fistula. 
Re-interventions
In the analysed group, re-interventions were nec-
essary in 6 (19%) patients. They are briefly discussed 
below.
In 1 patient with oesophago-mediastinal fistula 
and compression of the tracheal bifurcation, in whom 
double stenting was initially performed, oesophago- 
bronchial fistula occurred on the 53rd day after the 
procedure with oesophageal prosthesis transloca-
tion. Re-stenting was performed, and percutaneous 
endoscopic gastrostomy (PEG) was performed. The 
patient survived 113 days after re-stenting.
In the second patient, oesophago-tracheal fistula 
developed 35 days after bilateral stenting. A second 
oesophageal prosthesis was implanted and the pa-
tient died 5 days later.
In the third patient, fistula progression and pros-
thesis translocation was diagnosed on the 28th day 
after double stenting for the oesophago-tracheal fis-
tula. The oesophageal stent was removed, followed 
by re-stenting and PEG implantation. The patient 
survived for 24 days.
Table II. Clinical characteristics of patients before and after double stenting
Parameter Mean (range) Type of fistulas P-value
Type I Type II Type III
Patients    31 5 9 17
Mean degree of dyspnoea (range):
Before stenting 2.43 (0–3) 2.4 (2–3) 2.0 (2–2) 2.9 (2–3) < 0.00001
After stenting 0.34 (0–1) 0.6 (0–1) 0 (0–1) 0.29 (0–1)
Mean degree (range) of stricture in airway:
Before stenting 45% (30–70%) 46% (40–50%) 40% (30–50%) 50% (30–70%) < 0.00001
After stenting 0 0 0
Mean degree of dysphagia (range):  
Before stenting 2.59 (0–3) 2.6 (1–3) 2.66 (1–3) 2.52 (0–3) < 0.00001
After stenting 0.94 (0–1) 1.0 (0–1) 1.0 (1–0) 0.94 (0–1)
Mean weight loss (range) [kg]:
Before stenting 7.86 (0–20) 6.0 (0–12) 8.32 (4–15) 9.28 (3–20) 0.87
After stenting –0.48 (0–8) +1 (2–3) 2.44 (0–11) 0 (0–8)
Mean BMI (range) [kg/m2]:













Mean Karnofsky score (range):
Before stenting 50.4 (40–70) 52.2 (50–60) 52.2 (40–60) 46.8 (40–70) 0.00001
After stenting 68.3 (50–70) 68 (60–70) 65.5 (50–70) 70.6 (50–70)
Cause of death:
Cachexia 3 4 11
Dyspnoea 1 2 3
Haemorrhage 1 3 4
Mean survival time (range) [days] 67.1 68.4 (30–168) 71.8 (25–169) 66 (3–178) 0.3
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In the fourth patient, who underwent double stent-
ing for an oesophago-bronchial fistula, obliteration of 
the tracheal prosthesis by inflammatory granulation 
was diagnosed during the follow-up bronchoscopy 
on the 20th day after stenting. During patency resto-
ration the patient developed pneumothorax requiring 
pleural cavity drainage. He died after 28 days.
In the fifth patient oesophageal prosthesis migra-
tion occurred on the 10th day after double stenting 
for an oesophago-mediastinal fistula. Re-stenting 
and PEG implantation were performed. The patient 
survived for 38 days. 
In the sixth patient, in whom oesophago-trache-
al fistula was diagnosed 451 days after oesophageal 
stenting for unresectable squamous-cell carcinoma, 
tracheal PCASEMS was implanted. Fifty-eight days lat-
er the patient was re-admitted due to increasing dys-
pnoea and food aspiration. The tracheal PCASEMS was 
removed and a silicone Y-type stent and PEG were im-
planted. Oral and gastrostomy nutrition was resumed 
and the patient was discharged from the hospital on 
the 7th day after the procedure. He survived 169 days 
after oesophago-tracheal fistula diagnosis.
Discussion
Oesophago-respiratory fistula is a  severe com-
plication of advanced oesophageal or bronchial 
carcinoma. Its occurrence is estimated at 0.9–18%, 
resulting from the direct neoplastic infiltration and 
necrosis between the oesophagus, bronchi and me-
diastinum [10]. Analysis performed at the Memorial 
Sloan-Kettering Cancer Center in New York, during 
the period between 1926 and 1988, showed the 
presence of fistulas in 184 (4.5%) of 3,543 patients 
with oesophageal cancer. Duke University Medical 
Center data analysis, considering 2,440 patients di-
agnosed with oesophageal carcinoma, showed its 
occurrence in 0.9% of cases [11, 12]. 
Double stenting of the oesophagus and bron-
chial tree is the gold standard of treatment. The 
above-mentioned procedure is recommended by the 
American College of Chest Physicians [13], as well 
as the National Comprehensive Cancer Network 
(NCCN) [14]. 
Introduction of self-expanding oesophageal and 
airway stents as well as silicone Y-stents enables si-
multaneous, double stenting in patients with a malig-
nant oesophago-airway fistula. There is a wide spec-
trum of self-expanding oesophageal stents available, 
 Before After
 Median          25–75%          Min.–max.
Figure 1. Dyspnoea before and after airway 
stenting 
 Before After
 Median          25–75%          Min.–max.
Figure 2. Dysphagia before and after stenting of 
the oesophagus 
 Before After
 Median          25–75%          Min.–max.
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including fully and partially covered stents. These 
stents are characterised by a nearly 100% technical 
success rate, a migration rate of 10–20% and mortali-
ty below 5% [15]. The authors prefer partially covered 
stents, associated with low risk of migration and sim-
plicity of precise implantation with endoscopic con-
trol only, but on the other hand with a risk of tissue 
ingrowth in the uncovered ends of the stent.
For the airway, the authors prefer the silicone 
Y-stents or, depending of the location of stenosis, 
self-expanding metallic airway stents.
The introduction of a  silicone Y-type prosthesis 
and PCASEMS and PCESEMS significantly reduced 
the rate of complications [4, 15]. 
Double stenting enables the patient to breathe 
normally, facilitates oral nutrition, and improves 
the quality of life. The effectiveness of stenting has 
been demonstrated in many papers [16–19]. How-
ever, these procedures are associated with intra-, 
peri-, and postoperative complications [8, 20, 21]. 
The most feared is massive bleeding associated with 
bronchial tree patency restoration, which occurs in 
4–27% of patients, and the risk is highest for emer-
gency management [9, 17, 18]. Massive bleeding 
might occur intraoperatively, but also after that, even 
in long-term follow-up. In the analysed group, mas-
sive bleeding was the cause of death of 1 patient on 
the third postoperative day, and in 6 patients with-
in the long-term follow-up. To minimise the risk of 
bleeding, these procedures should be performed in 
reference centres by an experienced team. Binkert 
and Peterson also mentioned the occurrence of ear-
ly massive bleeding and patient death after bilater-
al stenting, when non-covered metallic prostheses 
were used [20]. Yakami et al. reported the occur-
rence of fatal bleeding as a result of atrial damage 
after oesophageal stenting and adjuvant radiother-
apy [21]. The second most frequent serious com-
plication is respiratory failure requiring mechanical 
ventilation. Herth et al. [22] noted its occurrence in 
7 (12%) patients. In our study group it was observed 
in 2 (7.9%) of 26 patients.
Other severe complications are instrumental 
damage to the bronchi, which reportedly occurs in 
2% [5] of patients. 
An oesophageal fistula is always considered as 
a poor prognostic factor. Freitag et al. analysed data 
obtained from 30 patients with bronchial fistulas, 
demonstrating mean survival of 110 days in the case 
of bilateral stenting, and only 24 days in the case of 
unilateral (airway) stenting [8]. Herth et al. reported 
the mean survival time of 236.6 days in a  group in 
which 65 patients underwent bronchial stenting, 37 
underwent oesophageal stenting, and 10 underwent 
bilateral stenting. Longer survival was observed after 
oesophageal and bilateral stenting. Also the location 
of the fistula had an impact on survival, with right 
bronchial fistula being associated with the shortest 
survival [22]. Our observations are consistent with 
those of Herth et al. showing that patients with type II 
fistulas lived longer than patients with type III fistulas.
Double stenting itself might be the cause of an 
oesophageal fistula, due to necrosis of the mem-
branous trachea. Thus, it is recommended to use 
covered metallic prostheses to the oesophagus 
without prophylactic stenting of the bronchial tree 
[23]. Such an approach, however, may be associat-
ed with increased risk of airway compression with 
acute, life-threatening impairment of ventilation. In 
patients included in our study, nitinol PCESEMS and 
PCASEMS were used. The uncovered ends of such 
prostheses limit the risk of migration, although ob-
struction due to granulation tissue overgrowth may 
occur. In such cases, these prostheses can be rela-
tively easily implanted one into another without the 
need of their removal. 
Due to disease progression, 4 (15%) of our pa-
tients required re-intervention because of fistula re-
currence. The cause of recurrence may be associated 
with disease progression, as well as previous stent-
ing, which can lead to compression and necrosis of 
the tissue between both prostheses. Those patients 
were once again scheduled for re-stenting with sat-
isfactory results.
In a  group of patients after stenting and adju-
vant therapy, fistula may recur in more than half of 
the patients [23–25]. These patients are usually in 
poor general condition, and re-intervention requires 
an experienced team. Considering our study group, 
mortality was not observed after re-intervention, al-
though 1 patient developed respiratory insufficien-
cy requiring mechanical ventilation. Survival after 
re-stenting ranged between 5 and 169 days (mean: 
54.1 days).
In some patients, in whom full coverage of nu-
tritional requirements is not expected, PEG should 
be considered. In the analysed group, PEG was per-
formed in 5 patients. 
The use of adjuvant chemotherapy remains con-
troversial, as some reports present disease progres-
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sion with fistula development. On the other hand, 
chemotherapy may lead to fistula closure [23–25]. 
Hamai et al. [25] reported a mean survival time of 103 
days, survival being longer in patients who received 
adjuvant therapy. Herth et al. demonstrated that the 
introduction of chemotherapy and/or radiotherapy is 
a poor prognostic factor of survival [22]. In our study, 
patients did not benefit from adjuvant therapy. Fifteen 
patients subjected to adjuvant chemo- and/or radio-
therapy did not benefit, and showed no weight gain. 
Double stenting is an effective and relatively safe 
palliative procedure, which improves the quality of 
life of patients with an oesophago-respiratory fistu-
la. These patients are usually in poor general condi-
tion, with progressive dysphagia, significant weight 
loss, and increasing respiratory insufficiency. Stent-
ing should be performed in a reference centre, by an 
experienced team capable of dealing with potential 
complications. 
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